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ABSTRACT: The methylation of amide nitrogen atoms can
improve the stability, oral availability, and cell permeability of
peptide therapeutics. Chemical N-methylation of peptides is
challenging. Omphalotin A is a ribosomally synthesized, macrocylic
dodecapeptide with nine backbone N-methylations. The fungal
natural product is derived from the precursor protein, OphMA,
harboring both the core peptide and a SAM-dependent peptide α-N-
methyltransferase domain. OphMA forms a homodimer and its α-N-
methyltransferase domain installs the methyl groups in trans on the
hydrophobic core dodecapeptide and some additional C-terminal
residues of the protomers. These post-translational backbone N-
methylations occur in a processive manner from the N- to the C-
terminus of the peptide substrate. We demonstrate that OphMA can
methylate polar, aromatic, and charged residues when these are introduced into the core peptide. Some of these amino acids alter the
efficiency and pattern of methylation. Proline, depending on its sequence context, can act as a tunable stop signal. Crystal structures
of OphMA variants have allowed rationalization of these observations. Our results hint at the potential to control this fungal α-N-
methyltransferase for biotechnological applications.
■ INTRODUCTION
Peptide macrocyclization offers a way to increase peptide
stability, membrane permeability, and rigidity.1 Chemical
modifications do likewise2 and include exocyclic amide
bonds,3 D-amino acids,4−7 tailoring of side chains,4,8,9 and
backbone (α-)N-methylation.10−14 Backbone N-methylation is
particularly potent, because it alters the energetic landscape of
backbone dihedral angles (profoundly impacting the peptide
secondary structure),15 shifts the amide bond cis/trans
equilibrium, disrupts hydrogen bonding,12 reduces hydro-
philicity of the amide backbone, and, in the macrocyclic
peptide cyclosporine A, allows “shape shifting”.12,16 Methyl-
ation is highly desirable for peptide therapeutics, since these
properties influence metabolic stability, cell permeability, oral
availability, and target selectivity.11
Conditions for chemical N-methylation of backbone amides
often result in epimerization of amino acids, removal of
protecting groups, and other unwanted side reactions.12,17−19
Thus, a biotechnological method of N-methylation would be
very valuable. Omphalotin A (Figure 1A), a nematotoxic
macrocyclic dodecapeptide natural product from the fungus
Omphalotus olearius, contains nine backbone N-methyla-
tions.20,21 For many years, omphalotin A was believed to be
produced via nonribosomal peptide synthesis (NRPS).
However, the peptide and its derivatives22,23 are derived
from a ribosomally synthesized precursor protein that is
processed by an enzymatic cascade comprising an S-
adenosylmethionine (SAM)-dependent peptide α-N-methyl-
transferase domain of the precursor protein (OphMA), a prolyl
oligopeptidase (OphP), member of the structurally charac-
terized POP family of macrocycle forming enzymes, an acetyl
transferase (OphD), and at least two cytochrome P450
monooxygenases (OphB1 and OphB2) (Figure 1B).24,25
OphMA consists of the N-terminal peptide α-N-methyltrans-
ferase domain (NMT, residues 1−251), a clasp domain
(residues 252−378), and the C-terminal substrate peptide
(residues 379−417).26,27 The precise boundary between the
clasp and C-terminal substrate peptide is somewhat arbitrary.
The C-terminal substrate peptide is subdivided into a leader
sequence (residues 379−399), the core peptide which
becomes omphalotin (residues 400−411), and a C-terminal
recognition sequence (residues 412−417) (see Figures 1B and
1C). The enzyme is an interlocked homodimer with a pseudo-
catenane structure.26 The peptide α-N-methyltransferase
domains of the two subunits form a “back to back” interface
while the clasp domain of one protomer wraps around the
“front” of the methyltransferase domain of the other protomer.
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The substrate peptide from one protomer is modified at the
active site of the other protomer (Figure 1C).26 The low
reactivity of the amide bond is overcome through a
combination of proton shuttling, conformation control, and
steric clash between SAM and an amide proton in the active
site.26,27 The core peptide is methylated in a distinct pattern,
where, for example, Ile402 is not methylated (skipped) while
Ile407 and Ile412 are methylated (see Figures 1A and 1B). A
similar skipping occurs at Val409, while Val401, 403, 404, and
406 are methylated. The basis of this methylation pattern,
which is conserved in two OphMA homologues (dbOphMA
from Dendrothele bispora and LedMA from Lentinula
edodes),24,25,27,28 has not been addressed.
One limitation on exploitation of OphMA in the
biotechnological production of N-methylated macrocycles is
the rather narrow known substrate profile (small hydrophobic
residues, e.g., Ala and Val). We show that the enzyme has a
broader profile and is able to methylate also large hydrophobic,
small polar, and even charged amino acids. We also
demonstrate that some mutations of the core peptide
profoundly alter the pattern of methylation, including residues
that act as a stop and alternative start signals. Using structural
analysis of the respective OphMA variants, we have been able
to rationalize some of the rules governing the regioselectivity of
the enzyme.
■ RESULTS
Core Peptide Substitutions Affect the Degree of
Methylation. Small hydrophobic residues (Val, Ile) at
positions 403, 404, 406, and 407 (Figure 1b) of the precursor
protein were mutated to Thr, Glu, Arg, Phe, or Pro to probe
effects of charge, size, and conformational rigidity. The
mutations were introduced in the context of the full-length
(including the C-terminal recognition sequence), N-terminally
His-tagged protein (see Figure 1).
Mutant protein expression was induced in E. coli BL21-
(DE3) for 72 h, and the degree of methylation was determined
as described previously.24 The mutant and wild-type proteins
eluted with the same retention time on a size exclusion column
consistent with a folded dimeric state. The most abundant
species of the wild-type protein showed complete methylation
of the core peptide (9-fold) with an additional methylation at
Val413 (Figure 2A).24 LC-ESI-MS extracted ion chromato-
grams (EIC) of proteolytic digests of the OphMA variants
were analyzed to identify the most abundant methylated
species for each variant (Figure 2). The number of
methylations of the most abundant species (judged by
integrated peak intensity) in each mutant was compared to
the native to judge methylation efficiency.
The introduction of Thr at positions 403 and 404 resulted in
similar methylation to wild-type (10-fold methylated species
most abundant) (Figure 2A and 2B). In I407T, methylation
was slightly reduced (9-fold). However, the introduction of
Thr at position 406 reduced methylation, with a 3-fold
Figure 1. Overview of omphalotin biosynthesis. (A) Structure of omphalotin A, with methyl groups highlighted in green. (B) The putative
biosynthetic gene cluster for omphalotin A. For OphMA, the methyltransferase domain is shown as a green sphere and the α-helices of the clasp
domain are shown in blue, respectively. The residues of the core peptide are colored in red. Methylated residues in the core peptide and the C-
terminal recognition sequence are marked with green circles. (C) Monomer of OphMAΔC6−Y98A (PDB ID: 5N0S) lacks the C-terminal
recognition sequence; the methyltransferase domain is green, the clasp domain is blue, the leader sequence is yellow, and the core peptide is red.
(D) Dimer of OphMAΔC6−Y98A where the second subunit is represented in transparent surface (cyan). SAM is represented by sticks.
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methylated species being the most abundant (Figure 2B). The
introduction of the large hydrophobic Phe generally decreased
methylation but the effect was dependent on the position
(Figure 2C). Substitution at position 403 yielded comparably
Figure 2. Methylation analysis of full-length OphMA core peptide variants under in vivo conditions. LC-ESI-MS analysis of methylation of (A)
OphMA wild type; (B) OphMA V403T, V404T, V406T, and I407T; (C) OphMA V403F, V404F, V406F, and I407F; (D) OphMA V403E,
V404E, V406E, and I407E; (E) OphMA V403R, V404R, V406R, and I407R; and (F) OphMA V403P, V406P, and I407P. Red dashed lines mark
the number of methylations states. Co-eluting contaminants are marked with a blue asterisk. The integrated peak intensity was used to estimate the
relative abundance of the peptide species.
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abundant monomethylated, dimethylated, trimethylated, and
tetramethylated species, while V404F yielded mainly mono-
methylated peptides. A tetramethylated species and, to a lesser
extent, a trimethylated species, resulted from a V406F
substitution, while the I407F mutant yielded mainly a
tetramethylated species with some pentamethylated species
(Figure 2C). Introduction of Glu also decreased the degree of
methylation in a position-dependent manner. Substitutions at
positions 403, 404, and 407 yielded peptides with 1, 2, and 5
methylations, respectively (Figure 2D). Substitution at
position 406 produced a mixture of similarly abundant
peptides containing 4, 5, or 6 methylations (Figure 2D).
Introduction of the large and positively charged Arg residue
strongly decreased the degree of methylation, irrespective of its
position (Figure 2E). At position 407, the dominant species
carried three methylations (Figure 2E). At positions 403, 404,
and 406, the dominant species was unmethylated, with the next
most abundant having two methylations (Figure 2E). Proline
was introduced at positions 403, 406, and 407 (Figure 2F). In
both V403P and V406P, the dominant species was
unmethylated, but V403P showed evidence for two methyl-
ations, while V406P showed evidence for two and four
methylations (see Figures 2F and Figure 3F, as well as Figure
S1f4 in the Supporting Information). The I407P variant had a
variety of species (two to four methylations) (Figure 2F), with
evidence of up to six methylations (see Figure 3F, as well as
Figure S1f6 in the Supporting Information).
Figure 3. Methylation pattern analysis of full-length OphMA core peptide variants under in vivo conditions. Peptides detected by LC-ESI-MS were
further analyzed by HPLC-ESI-MS/MS. The most abundant (left) and most methylated (right) species are shown. For some species, more than
one isoform was detected. In these cases, all detected isoforms are listed. Wild-type OphMA is shown in panel (A); Thr substitutions are shown in
panel (B); Phe substitutions are shown in panel (C); Glu substitutions are shown in panel (D); Arg substitutions are shown in panel (E); and Pro
substitutions are shown in panel (F). Substitutions are shown in red. Solid green circles indicate methylated residues confirmed by MS/MS, while
solid yellow circles are assumed to be based on the number and pattern of methylation but they are not experimentally confirmed by MS/MS.
ACS Chemical Biology pubs.acs.org/acschemicalbiology Articles
https://dx.doi.org/10.1021/acschembio.0c00237
ACS Chem. Biol. 2020, 15, 1901−1912
1904
Core Peptide Substitutions Alter the Pattern of
Methylation. The patterns of methylation of both the most
abundant and highly methylated species were analyzed by
HPLC-ESI-MS/MS (see Figure S1 in the Supporting
Information), and the results are summarized schematically
in Figure 3.
Thr substitutions at 403, 404, and 407 showed a wild-type
methylation pattern from Val401 to Val413 (skipping Ile402,
Val409, and Ser412) (see Figure 3B, as well as Figure S1). In
V406T, methylation terminated at position 404 but was wild-
type to this point (see Figure 3B, as well as Figures S1b5 and
S1b6 in the Supporting Information).
Figure 4. Methylation analysis of selected ΔC6 and full-length OphMA core peptide variants after in vitro SAM incubation. LC-ESI-MS was used
to measure the extent and estimate the relative abundance of methylated species: (A) selected OphMAΔC6 Phe-substitutions, (B) selected full-
length OphMA Glu-substitutions, and (C) selected full-length OphMA Pro-substitutions. Contaminants are marked with a blue asterisk.
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In contrast, the introduction of Phe resulted in a significantly
altered methylation pattern. V403F, V406F, and I407F
mutants showed a pattern where Ile402 was, in contrast to
the wild-type situation, methylated (see Figure 3C, as well as
Figures S1c2, S1c4, and S1c6 in the Supporting Information).
The introduction of Phe terminated methylation in most
mutants either one or two residue N-terminals to the Phe (see
Figures 2C and 3C, as well as Figures S1c1, S1c3, S1c5, and
S1c7 in the Supporting Information).
Examination of the most abundant peptides in the Glu
mutants revealed that, generally, methylation ended immedi-
ately prior to the Glu residue (with a wild-type methylation
pattern; see Figure 3D, as well as Figures S1d1−S1d8 in the
Supporting Information). Analysis of the most highly
methylated species revealed that methylation of Phe and Glu
residues by OphMA was possible (see Figures 2C and 2D, and
Figures 3C and 3D).
The presence of Arg terminated methylation prior to the Arg
(see Figure 3E, as well as Figures S1e3, S1e4, S1e7, and S1e8
in the Supporting Information). Arg itself was not methylated
by OphMA. Analysis of the doubly methylated peptides
isolated from V403R, V404R, and V406R showed methylation
C-terminal to Arg with a profoundly disrupted methylation
pattern (see Figure 3E, as well as Figures S1e1, 2S1e, S1e5, and
S1e6 in the Supporting Information). Pro, which cannot be
methylated, appeared able to function as an alternate start
(V403P) or as a stop (V406P, I407P) signal for methylation,
depending on its location (see Figures 2F and 3F, as well as
Figures S1f1−S1f6 in the Supporting Information).
In vitro Methylation Analysis for OphMA Variants.
Previous work showed that partially methylated OphMA active
site mutants can be purified from E. coli and further methylated
in vitro upon incubation with SAM.26 We applied this
procedure to the mutants where methylation appeared to be
halted (stalling mutants), V404E, V406E, V403P, V406P,
I407P, ΔC6-V403F, ΔC6-V404F, and ΔC6-V406F, as well as
the double mutant ΔC6-G405A/V406F. The prefix abbrevia-
tion ΔC6 denotes the deletion of residues 412−417, yielding a
protein that is easier to crystallize and characterize than the
full-length protein but is a valid model for the full-length
protein.26 The most abundant C-terminal peptide of
OphMAΔC6 is 7-fold methylated, with a pattern identical to
the wild-type protein (see Figures 4 and 5).
After 20 h of induction in E. coli, most (with 71% relative
abundance) of OphMAΔC6 was already completely (7-fold)
methylated (see Figure 4A and Table 1).26 Full-length OphMA
was not completely methylated under these conditions, but the
relative abundance of the 10-fold methylated species was
Figure 5. Methylation pattern for core peptide mutants of OphMA or ΔC6 after in vitro SAM incubation. The methylation pattern of the most
abundant (left side) and most methylated (right side) species: (A) OphMAΔC6-variants V403F, V404F, V406F, and G405A/V406F; (B)
OphMA-variants V404E and V406E; (C) OphMA-variants V403P, V406P, and I407P. Color coding is as described in Figure 3.
Table 1. Percentage of the Three Most Abundant
Methylated Species of Selected OphMA Variants Used in
the In Vitro Assaysa
OphMA variant
most abundant
species (a. sp.) second a. sp. third a. sp.
ΔC6 7 Me, 71% 5 Me, 10% 6 Me, 7%
ΔC6-V403F 4 Me, 30% 3 Me, 19% 1 Me, 16%
ΔC6-V403F + SAM 4 Me, 44% 3 Me, 20% 5 Me, 14%
ΔC6-V404F 2 Me, 45% 3 Me, 24% 1 Me, 23%
ΔC6-V404F + SAM 2 Me, 41% 3 Me, 26% 1 Me, 22%
ΔC6-V406F 0 Me, 54% 6 Me, 10% 3 Me, 10%
ΔC6-V406F + SAM 7 Me, 41% 6 Me, 23% 5 Me, 15%
ΔC6-G405A/V406F 2 Me, 31% 3 Me, 30% 4 Me, 17%
ΔC6-G405A/V406F
+ SAM
3 Me, 30% 4 Me, 20% 6 Me, 19%
OphMA 3 Me, 23% 10 Me, 20% 5 Me, 20%
V404E 2 Me, 57% 1 Me, 25% 0 Me, 10%
V404E + SAM 2 Me, 74% 3 Me, 12% 1 Me, 7%
V406E 4 Me, 44% 5 Me, 22% 3 Me, 10%
V406E + SAM 6 Me, 44%, 5 Me, 20% 7 Me, 16%
V403P 0 Me, 47% 1 Me, 31% 2 Me, 12%
V403P + SAM 3 Me, 19% 2 Me, 17% 1 Me, 17%
V406P 2 Me, 69% 0 Me, 13% 1 Me, 10%
V406P + SAM 2 Me, 78% 3 Me, 5% 1 Me, 5%
I407P 2 Me, 32% 1 Me, 21% 3 Me, 19%
I407P + SAM 4 Me, 36% 3 Me, 17% 2 Me, 16%
aThe relative abundance is determined by integrating the EIC peaks
and calculating the ratio between the integration of a specific species
and the sum of the integrations of all species.
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already significant (see Figure 4B and Table 1). OphMAΔC6-
V403F was mostly 4-fold methylated, similar to the in vivo
results for the full-length OphMA V403F variant. Incubation of
this protein with SAM for three days resulted in a shift to more
methylated species with evidence of methylation of Phe403
(see Figures 4A and 5A, as well as Figures S2a and S2b in the
Supporting Information). In contrast, the ΔC6-V404F variant
was purified as monomethylated, dimethylated, and trimethy-
lated species whose distribution changed little upon incubation
with SAM. Compared to the full-length V404F variant, the
truncated protein revealed a higher degree of methylation
(Figure 4A), with clear evidence that Phe404 was methylated
(Figure S2d in the Supporting Information). OphMAΔC6-
V406F purified with the unmethylated species being dominant
but upon incubation with SAM became completely (7-fold)
methylated (Figure 4A). The methylation pattern of this
species was the same as that for wild-type OphMAΔC6 and
Phe406 was methylated (see Figure 5A, as well as Figure S2e in
the Supporting Information). The double mutant ΔC6-
G405A/V406F yielded a range of methylated species (see
Figure 5A, as well as Figure S2g in the Supporting
Information), with the 2-fold methylated species being most
abundant (Figure 4A). Only a limited increase in methylation
occurred upon incubation with SAM (Figure 4A).
The full-length OphMA-V404E variant was purified as a
mixture of monomethylated and dimethylated species (with
methylation at Val401 and Val403) from E. coli (see Figure 4B,
as well as Figure S2h in the Supporting Information),
consistent with the in vivo data. Incubation with SAM resulted
in accumulation of a dimethylated species and proteins with
additional methylations at Glu404, Gly411, and Val413 (see
Figure 4B, as well as Figure S2i in the Supporting
Information). OphMA-V406E purified as a mixture of species
(Figure 4B), such as the in vivo analysis. Incubation with SAM
yielded a 6-fold methylated species but residues 406 to 410
were skipped (Figure 5B). An 8-fold methylated species was
detected, suggesting the methylation of Ile402 and Val409 (see
Figure 5B, as well as Figure S2k in the Supporting
Information).
OphMA-V403P was purified mostly as unmethylated protein
with some monomethylated and dimethylated species (Figure
4C). Upon incubation with SAM, further methylation up to a
maximum of 7-fold was observed (Figure 4C). MS/MS-
analysis suggested that methylation occurred at a variety of
positions but only after the introduced Pro residue (see Figure
5C, as well as Figure S2m in the Supporting Information).
OphMA-V406P was purified as dimethylated species (Val401
and Val403), with evidence for a very small amount of Val404
Figure 6. Active site view of several “stalling” mutants: (A) OphMAΔC6-V404F has Phe404 at i+1 position; (B) OphMA-V404E has Glu404 at
position i and a different conformation of Tyr98; (C) OphMA-V406P has a cis-peptide conformation; (D) OphMA-I407P has a trans-peptide
conformation; and (E) superimposition of OphMA-V406P (purple), OphMA-V404E (orange), OphAMAΔC6−V404F (silver), OphMA-I407P
(green), and, for comparison, OphMA-Y63F (cyan, PDB ID: 5N0N,26 methylated V403 at position i).
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methylation upon incubation with SAM (see Figures 4C and
5C, as well as Figures S2n and S2o in the Supporting
Information). Similar to the in vivo analysis, OphMA-I407P
was a mixture of monomethylated, dimethylated, trimethy-
lated, and tetramethylated species (Val401, Val403, Gly404,
and Val405) (see Figures 4C and 5C, as well as Figure S2p).
Incubation with SAM resulted in a decrease of the
dimethylated and a concomitant increase in the tetramethy-
lated species (Figure 4C). MS/MS analysis revealed 5- and 6-
fold methylated species (at Gly411 and Val413; see Figure 5C,
as well as Figure S2q in the Supporting Information). Our
results differ from dbOphMA, where I407P abolished
methylation and V403P yielded a single methylation.27
Structural Analysis of Some OphMA Core Peptide
Variants. The crystal structures of OphMA-V404E, Oph-
MAΔC6-V404F, OphMA-V406P, and OphMA-I407P in
complex with SAH were determined at resolutions of 1.9,
1.8, 1.6, and 2.2 Å, respectively (Table S1). The overall
structures of the four mutants are unchanged from
OphMAΔC6-SAH (PDB ID: 5N0Q).26
The structure of V404F showed the clear electron density
for SAH, methylation at Val401, and methylated Val403 at the
active site (denoted as position i, following the previous
nomenclature26) (see Figure 6A, as well as Figure S3 in the
Supporting Information). The backbone of C-terminal
substrate peptide and the active site residues overlap well
with active site mutant OphMA-Y63F, with a root-mean-
square deviation (rmsd) of 0.76 Å (PDB ID: 5N0N26) (Figure
6E). Phe404 sits at i+1 and interacts with many of the active
site residues but does not significantly perturb their arrange-
ment. In the V404E structure, the electron density of chain B
was clear and modeled as a trimethylated species with
methylated Glu404 at position i and SAH bound at the active
site (see Figure 6B, as well as Figure S3). The conformation of
the introduced Glu404 requires Tyr98 to adopt a conforma-
tion that was not observed previously and would seem
“inactive” (see Figure 6B, as well as Figure S4 in the
Supporting Information). In chain A, the electron density of
the substrate peptide was heterogeneous,26 and our best model
has methylated Val401 (monomethylated species) at position i
with SAH bound to the protein. Heterogeneity in the electron
density has been suggested26 to arise from heterogeneity of
methylation in the protein and may be unavoidable for some
samples, such as V404E (see Figures 4B and 5B).
The structure of V406P shows the clear electron density for
Asn396 to Gly408 with Val401 and Val403 methylated (Figure
S3b), consistent with in vitro analysis (Figure 4D). The
substrate peptide adopts the same conformation as that seen in
the native structure26 until it reaches Val404. The introduction
of the Pro residue has resulted in a cis-peptide bond between
Gly405 and V406P (positions i+2 and i+3) (Figures 6C and
6E), which prevents further substrate translocation. The
structure of I407P shows a well-resolved C-terminal peptide
from Gly397 to Gly408 with clear density for methylated
Val401 and Val403 (position (i). I407P at position i+4 has a
normal trans-peptide conformation (see Figure 6D).
■ DISCUSSION
Methylation of peptide amide N atoms is desirable but
chemically challenging. The enzyme OphMA is unusual in that
the α-N-methyltransferase domain and its substrate (core
peptide) are part of the same polypeptide. The catalytic
domain of the enzyme binds the core peptide and a SAM
molecule in a hydrophobic tunnel that is formed by the
dimeric arrangement of two OphMA molecules. For
omphalotin biosynthesis, the core peptide is cleaved out and
macrocyclized by the prolyloligopeptidase OphP; the remain-
der of the enzyme is assumed to be discarded.24 The covalent
attachment of the substrate to the enzyme renders the
otherwise very hydrophobic (and insoluble) substrate soluble
and increases its local concentration and, hence, the rate of the
reaction. The side chains of the core peptide are not
recognized by the enzyme26 and, thus, the covalent linkage
may also compensate for the lack of recognition. Despite this
apparent lack of recognition, there is a distinct methylation
pattern (skipping of some residues), but what underpins this is
unknown.
Sequence alignments of fungal OphMA homologues show
that the core peptide sequences are biased toward hydrophobic
(Gly, Ile, Val, Leu) and small hydrophilic (Thr) amino acids.28
Since evolution would be expected to select for the properties
of the compound, the enzymes may be naturally promiscuous,
allowing mutations of the core sequence without requiring
compensating mutations in the catalytic machinery. Substrate
plasticity has previously been investigated by replacing the
entire core peptide with unrelated sequences of other
backbone N-methylated peptide natural products. This showed
that OphMA was able to methylate residues in these other
sequences but with patterns different from either omphalotin
or the desired natural product.24 Here, we report a systematic
analysis of single substitutions at different positions of the core
peptide by small hydrophilic (Thr), large charged (Arg or
Glu), large hydrophobic (Phe), and conformationally rigid
(Pro) residues. Threonine was well-tolerated at all positions,
although the degree of methylation was slightly lower than
wild-type. We attribute this slight decrease in the methylation
efficiency to the mismatch between the hydrophobic tunnel
and the hydrophilic side-chain hydroxyl of threonine.
Consistent with our results, the homologue dbOphMA natively
methylates a threonine residue.24,25,27 The introduction of Arg
effectively abolishes methylation, except in one variant, I407R,
where three residues N-terminal to Arg were efficiently
methylated before halting at Val404. The large positively
charged residue is likely to be incompatible with the
hydrophobic substrate tunnel.
Glu does not have such a pronounced effect as Arg, and
methylation proceeds up to the position of the introduced Glu,
where it stalls. The stalling is not absolute and the enzyme can
methylate Glu albeit slowly and we detect peptides with
methylation C-terminal to the introduced Glu (see Figures 2D,
3D, 4B, and 5B), suggesting Glu can translocate through the
active site. The crystal structure of SAH-bound OphMA-
V404E, which has a methylated Glu at the active site, reveals
that catalytically essential residue Tyr9826 adopts an “inactive”
conformation to accommodate Glu. We hypothesize that this
distortion of the active site is responsible for the very slow
methylation rate (stalling).
The presence of phenylalanine altered both the pattern and
degree of methylation (N-terminal and C-terminal to site of
mutation) but its effect was highly dependent on its position.
Simple modeling shows that the larger phenylalanine side
chain requires a rearrangement of the core peptide and/or the
enzyme to avoid severe van der Waals clashes when Phe
occupies either the i−1, i, or i+2 positions. Since methylation
was observed, these changes must be possible, but we suggest
they cause multiple stalling events. The clashes at the i+2 site
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explain the observed stalling of methylation two residues
before the Phe in three such variants (see Figures 2C and 4A).
In the V403F mutant, Phe would occupy the i+2 position as
this is the starting configuration for the protein; its subsequent
translocation to i+1 would reduce clashes but further
translocation to position i would be disfavored (second stalling
event). We propose, with Phe stalling further translocation,
that Ile402 is held at position i and methylated (rather than
skipped). Finally, modeling suggests that there is potential for
π-stacking between a Phe at the i−2 position and Tyr63, giving
rise to third stalling event, but arising from preserving favorable
interactions rather than avoiding clashes. This event would
explain the pattern observed for OphMA variants V403F and
V404F where methylation apparently stalled two residues after
the introduced Phe.
Proline cannot be a substrate for the enzyme and would
cause extensive steric clashes at the active site. The
introduction of proline at position 403 of OphMA completely
eliminates methylation. Prolonged incubation with SAM yields
some methylation but starting after Pro403 and with
heterogeneous patterns suggestive of multiple start sites. We
suggest that this arises as a result of the Pro inducing
conformations in the substrate that mimic (imperfectly) the
natural start site after Pro399 and consequent “misfolding” of
some protein. Proline introduced at either residue 406 or 407
gives rise to wild-type methylation which stops at Val403 or
Gly405, respectively. Structural analysis of the V406P mutant
reveals that the proline adopts a cis-peptide conformation with
Gly405 which acts as a stop signal at n−2 to the proline. I407P
shows that the proline adopts a trans conformation, which acts
as a stop signal, but at n−1 relative to the proline. The small
amount of methylation at Val404 in V406P could arise from a
small amount of trans-configured peptide.29,30
Unexpectedly, the enzyme is able to process large residues
such as Phe and the negatively charged Glu. In many cases, the
heterogeneous methylation in vivo can be driven to completion
by incubation in vitro with SAM. This inherent promiscuity of
the enzyme indicates synthetic potential. However, the
tolerance of the active site is not limitless (Arg cannot be
processed and appears unable to enter the active site tunnel).
Peptide flexibility appears to be important, because the V406F
mutant (Phe follows Gly405) was methylated to a much higher
degree than other Phe variants. The double variant G405A/
V406F, which reduced the flexibility, showed a reduced degree
of methylation, compared to V406F (Figure 4A), which is
consistent with this suggestion.
There are three Ile residues in the wild-type core peptide,
two of which are methylated and one is skipped; thus, the
methylation pattern is not a function of the nature of the
residue. Our data provide evidence that the pattern arises from
the translocation of the six residues of the substrate peptide
that are in contact with the enzyme substrate tunnel during
catalysis (positions i−3 to i+2). We suggest the analogy of a
clutch as means to think of the methylation pattern. When the
clutch is disengaged, the gears mesh and this is equivalent to
peptide translocation and methylation. When the clutch is
engaged, the gears rotate freely and this equivalent to skipping,
where the peptide moves through the active site faster than it
can be positioned for catalysis. In the V403F, Ile is stuck at the
active site (the gears mesh) long enough for it to be
methylated. In the Glu variants, the active site Try98 is
displaced (gears rotate freely) and this results in extensive
skipping before methylation can resume. In the same way, we
suggest that distortion of the active site during Pro passage
results in multiple skipping explaining the pattern of
methylation C-terminal to Pro in I407P (see Figures 3F and
5C).
By introducing point mutations in the core peptide sequence
of OphMA, we show that the substrate promiscuity of this
peptide α-N-methyltransferase is larger than anticipated from
the naturally occurring core peptide sequences of fungal
OphMA homologues.28 An additional challenge for biotechno-
logical applications of OphMA, besides substrate promiscuity,
is how to control the enzyme to produce a homogeneously
methylated product. In this regard, we have been able to
identify some of the factors and mechanisms controlling the
efficiency and the pattern of OphMA-mediated peptide
methylation. These insights will be useful for applications
like the production of de novo libraries of multiply backbone N-
methylated peptides for the development of peptide
therapeutics.31
■ MATERIALS AND METHODS
Materials and General Procedures. Plasmid DNA purification
from E. coli cultures was performed using the Nucleospin spin
columns (Macherey-Nagel). DNA from PCR, restriction digests, and
ligations was purified either first by agarose gel electrophoresis or spin
columns. DNA concentration was determined spectrophotometrically
using NanoDrop (Thermo Fisher Scientific). DNA manipulations
were performed according to manufacturer recommendations or using
standard procedures.32 DNA sequencing, synthesis, and purification
by desalting of oligonucleotides was performed by Microsynth AG.
Primers for full-length V406P, V404E, and OphMAΔC6−V404F
were purchased from IDT. Fast-digest restriction endonucleases,
Phusion DNA-polymerase, and T4 DNA ligase were purchased from
Thermo Scientific or New England Biolabs. Crystallization screens
were purchased from Hampton Research and Molecular Dimensions.
EDTA-free Protease Inhibitor Cocktail (cOmplete) were bought from
Roche. Other chemicals were purchased from Sigma−Aldrich/Fluka.
Bacterial Strains and Plasmids. Escherichia coli strains DH5α
and BL21 (DE3) were used for cloning and protein production,
respectively. Plasmids PMA997 (pET24-OphMA), PMA1004
(pET24-His8-OphMA), and PMA1304 (pET24-His8-OphMA-
TEVcs-ΔC6) were described previously.24 Plasmids constructed in
this study are listed in Table S2 in the Supporting Information.
Construction of Core Peptide Mutants. Primers used for
plasmid constructions are listed in Table S3 in the Supporting
Information. A PCR fragment was generated using primers 24 and 25
and plasmid PMA997 as a template. The fragment was digested with
BamHI and EcoRI and ligated into accordingly digested plasmid
PMA1304 to obtain plasmid PMA1471 encoding His8-tagged wild-
type OphMA.
The plasmids encoding the OphMA core peptide mutants were
generated using overlap extension PCR and plasmid PMA1471 as a
template. A first PCR product for overlap extension was generated
using primer 27, together with 28, 30, 32, 34, 36, 38, 40, 42, 44, 46,
48, 50, 52, 54, 56, or 58. A second PCR product was obtained using
primer 26, in combination with 29, 31, 33, 35, 37, 39, 41, 43, 45, 47,
49, 51, 53, 55, 57, or 59. The resulting PCR products were assembled
using the external primers 27 and 26. After digestion with HindIII and
BamHI, the resulting fragments were ligated with the accordingly
digested plasmid PMA1304.
The plasmids encoding the OphMA Pro mutants were created by
the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher
Scientific), using plasmid PMA1004 as template and respective
primer pairs according to the manufacturer’s protocol.
A TEV cleavage site was introduced after the His8-tag into
constructs coding for the wild-type versions of both full-length
OphMA and OphMAΔC6 using PMA1004 as a template.24,33 The
resulting plasmids were used as template to generate OphMA core
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peptide mutants for in vitro assays and crystallization by a reported
protocol.26,33 Plasmids were sequenced using T7 primers.
Protein Production. Protein production was performed as
described in refs 24 and 26, with small modifications. A preculture
was grown in LB medium containing 50 μg/mL kanamycin at 37 °C.
The main cultures were inoculated to OD600 of 0.01 in 1 L of TB
medium (2.4% (w/v) yeast extract (Oxoid AG), 1.2% (w/v)
Tryptone (Oxoid AG), additionally containing 0.4% (w/v) glycerol,
0.17 M KH2PO4 and 0.72 M K2HPO4) supplied with 50 μg/mL
kanamycin. For full methylation, cultures were grown at 37 °C to
OD600 = 1.5−2 and chilled on ice before induction with 0.2 mM
isopropyl-β-D-thiogalactopyranoside (IPTG), which was followed by
incubation for 72 h at 16 °C. OphMA mutants used for in vitro assay
and crystallization were expressed for 20 h at 16 °C.26 In vitro
methylation was performed as previously described.26
Protein Purification. Protein purification was performed as
described previously,24,26 with small modifications. After induction for
the required amount of time, the bacterial cells were spun down at
8000g for 5 min at 4 °C. The cell pellets were resuspended in 25 mM
Tris-HCl (pH 8.0) additionally containing 100 mM NaCl, 10% (v/v)
glycerol, and 20 mM imidazole. After a freeze−thaw cycle, 0.2 mg/mL
lysozyme and EDTA-free cocktail protease inhibitor (Roche) was
added and incubated for 1 h on ice. Cells were disrupted using a
French press, and the debris was removed by centrifugation at 13 000g
for 30 min. After that, the cell supernatant was equilibrated with
rotation with Ni-NTA beads (Thermo Scientific) at 4 °C for 1 h. The
collected beads were washed, and the protein was eluted in 25 mM
Tris-HCl (pH 8.0) containing an additional 100 mM NaCl, 10% (v/
v) glycerol, and 400 mM imidazole.
The sample was concentrated using an Amicon Ultra-4 centrifugal
filter device with a molecular-weight cutoff of 30 kDa (Millipore).
One milliliter (1 mL) of protein sample was loaded into a Superdex-
200 Increase column (GE Healthcare), which was pre-equilibrated
with 25 mM Tris-HCl (pH 8.0), 10% (v/v) glycerol, and 100 mM
NaCl. Protein concentration was determined using the Pierce BCA
protein assay (Thermo Scientific) and bovine serum albumin as a
standard.
All proteins were further purified by gel filtration as described
previously26 and used fresh or stored at −80 °C.
HPLC-ESI-MS/MS High-Energy Collision Dissociation (HCD).
The C-terminal tryptic peptides of OphMA variants were analyzed by
HPLC-ESI MS/MS as described previously.24 The purified proteins
were concentrated to 4 mg mL−1 in 25 mM Tris-HCl (pH 8.0), 10%
(v/v) glycerol and 100 mM NaCl and supplied with protease. All
mutants except for Arg mutants were supplied with trypsin in a molar
ratio of 1:80 and incubated in a glass vial for 16 h at 37 °C in a final
volume of 20 μL. Arg mutants were treated with endoproteinase Lys-
C in a molar ratio of 1:20 and incubated at 37 °C for 16−24 h in a
final volume of 27.5 μL.
After proteolytic digestion, 3 or 5 μL of sample was used for MS/
MS analysis. The resulting peptides were separated in increasing
acetonitrile gradient on the Phenomenex Kinetex 2.6 μm C18 column
(150 mm × 2.1 mm) on Dionex Ultimate 3000 UHPLC system and
subsequently analyzed with targeted MS/MS using Thermo Scientific
Q Exactive mass spectrometer.24
In vitro methylated proteins were digested at 37 °C overnight using
sequencing-grade trypsin (Promega). Data were recorded on a Sciex
5600+ mass spectrometer equipped with the Eksigent 2D Ultra
NanoLC system using a Thermo Scientific PepMap C18 column (75
μm × 15 cm) and trap (2 cm). MS/MS data were extracted using the
SCIEX PeakView software and analyzed using the Mascot 2.6 search
engine (Matrix Science) against sequences of OphMA mutants. MS/
MS interpretation was verified manually.
Crystallization, Data Collection, and Structure Determina-
tion. Freshly prepared V404F, V404E, V406P, and I407P were
crystallized by mixing 1 μL of protein (30−50 mg/mL) preincubated
with 3 mM SAM with 1 μL of reservoir solution (0.3−0.4 M KSCN,
1.8−2.4 M sodium malonate, and 0.1 M bicine buffer pH 8.5−9.3)).
Crystals were obtained at 16 °C within 1 week using the hanging drop
diffusion method. These crystals were flash frozen in the cryo
protectant containing 0.1 M bicine (pH 9.0), 0.3 M KSCN, and 2.5−
3.0 M sodium malonate.
X-ray diffraction data were recorded at Diamond Light Source
beamline I03 (V404E and V406P), I24 (ΔC6-V404F), or I04
(I407P). Data were reduced, integrated, and scaled using xia2.34 The
structures were solved by molecular replacement with OphMAΔC18
(PDB ID: 5N0O) as the initial search model using Phaser.35
Structures were further refined and improved using Coot,36 refmac,37
and PDB_REDO.38 The final models were verified with MolPro-
bity.39 The statistics of the data collection and refinement are
summarized in Table S1 in the Supporting Information. All
crystallographic figures were generated using Pymol (Schrödinger).
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